Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 5

1. 2026-05-01
   Company announcements

   Today announced that on April 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 29,400 shares of the Company’s common stock, with a per share exercise price of $6.18.

2. 2026-02-20
   Listing / IPO

   Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 18,348,624 shares of its common stock at a price to the public of $5.45 per share.

3. 2024-11-19
   Earnings releases

   The company reported a net loss of $10.6 million, attributing this mainly to changes in warrant liabilities.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

1. 2025-12-23
   Regulatory

   the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award of 8,224 restricted stock units ("RSUs") to a new employee under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan ("Inducement Award Plan") in connection with their commencement of employment.

2. 2025-03-26
   Earnings releases

   For the year, the company reported profit of \$7.2 million, or \$1.04 per share. Revenue was reported as \$68.7 million.

3. 2024-05-08
   Business contracts

   Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will issue and sell in a non-brokered private placement to members of its senior leadership team, including the Chief Executive Officer, 25,000 shares of its common stock at a price of $12.00 per share, representing a 13.5% premium to the closing price of its common stock immediately preceding the signing of the subscription agreement, for an aggregate amount of $300,000 (the “Private Placement”).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

1. 2026-02-26
   Company announcements

   Adagio became a major partner of the FDJ-UNITED SUEZ women’s cycling team

2. 2025-02-14
   Listing / IPO

   Adagio Therapeutics Inc., of Waltham, Mass., launched its upsized IPO at the $17 per share midpoint to raise $309 million.

3. 2025-01-10
   Leadership changes

   Adagio, the European leader in aparthotels, announces the appointment of Sophie Mestiri as Chief Human Resources Officer and member of the Executive Committee.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

1. 2026-04-19
   Board updates

   Now, to be fair to Novavax, the company did add two members to its board in 2025, though one director, Richard Douglas, has held a board seat for more than a quarter of a century.

2. 2026-02-27
   Earnings releases

   Novavax reported a fourth-quarter earnings shift to a profit of 11 cents, compared to a loss of 51 cents a year ago, with revenue hitting $147 million, a 67% increase year-over-year.

3. 2026-01-21
   Business contracts

   Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix‑M adjuvant technology. Under the non‑exclusive agreement, Pfizer gained access to Novavax's technology that boosts immune responses to vaccines. In return, Novavax received an upfront payment of $30 million. The company also became eligible for up to an additional $500 million in potential development and sales milestone payments. Furthermore, the deal included tiered, mid‑single‑digit percentage royalty payments to Novavax on sales of any Pfizer product that incorporated the Matrix‑M adjuvant.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

1. 2026-02-27
   Business contracts

   Astellas Pharma Inc. and Vir Biotechnology Inc. have signed a global co-development pact to advance VIR-5500, Vir’s PRO-XTEN dual-masked CD3 T-cell engager targeting prostate-specific membrane antigen for treating prostate cancer. Under the deal terms, San Francisco-based Vir will receive $335 million in up-front and near-term payments, including $240 million in cash, $75 million in equity investment and a $20 million near-term milestone. Vir is also eligible to receive up to $1.37 billion in development, regulatory and sales-based milestones plus royalties on ex-U.S. sales.

2. 2026-02-24
   Listing / IPO

   Vir Biotechnology, Inc. (Nasdaq: VIR ), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer $200,000,000 of shares of its common stock in an underwritten public offering.

3. 2026-02-24
   Company announcements

   Vir Biotechnology Inc (NASDAQ: VIR) entered a partnership with Astellas to develop a prostate cancer therapy, securing significant upfront and milestone payments.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.